|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2009-8-24
|
|
pubmed:abstractText |
Masitinib is a tyrosine kinase inhibitor with a pre-clinical profile suggesting greater affinity and selectivity in vitro for the wild-type c-Kit receptor and its juxtamembrane mutation than imatinib.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1879-0852
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
45
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2333-41
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19541476-Administration, Oral,
pubmed-meshheading:19541476-Adult,
pubmed-meshheading:19541476-Aged,
pubmed-meshheading:19541476-Antineoplastic Agents,
pubmed-meshheading:19541476-Dose-Response Relationship, Drug,
pubmed-meshheading:19541476-Female,
pubmed-meshheading:19541476-Gastrointestinal Stromal Tumors,
pubmed-meshheading:19541476-Humans,
pubmed-meshheading:19541476-Male,
pubmed-meshheading:19541476-Maximum Tolerated Dose,
pubmed-meshheading:19541476-Middle Aged,
pubmed-meshheading:19541476-Receptor Protein-Tyrosine Kinases,
pubmed-meshheading:19541476-Thiazoles,
pubmed-meshheading:19541476-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.
|
|
pubmed:affiliation |
Département de Médecine, Institut Gustave Roussy, Université Paris XI, Service des Innovations Thérapeutiques Précoces, 94805 Villejuif, France. soria@igr.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
